The state of the art of tumor molecular imaging targeting PD-1/PD-L1 pathway
10.3760/cma.j.issn.2095-2848.2017.12.015
- VernacularTitle:靶向PD-1/PD-L1通路的肿瘤分子显像研究进展
- Author:
Dan LI
1
;
Siyuan CHENG
;
Xiaohua ZHU
Author Information
1. 华中科技大学同济医学院附属同济医院核医学科
- Keywords:
Neoplasms;
Programmed cell death 1 receptor;
Antigens,CD274;
Molecular imaging;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2017;37(12):809-814
- CountryChina
- Language:Chinese
-
Abstract:
Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) path-way has emerged as a critical target for cancer immunotherapy,and monoclonal antibodies that block either side of this inhibitory interaction have demonstrated impressive activity across a broad set of cancer subtypes.Clinical studies have shown that tumor PD-L1 expression is associated with clinical stages and poor prognosis.Tumor PD-L1 expression detection may help to screen the patients who are most likely to be benefit from anti-PD-1/PD-L1 therapy and evaluate the prognosis.Molecular imaging technology such as PET,SPECT and optical imaging may be the modalities that allowing for noninvasively dynamic detection and overall evaluation of multiple biomarkers.This review focuses on the state of the art of tumor molecular imaging targeting PD-1/PD-L1 pathway.
